Founded in 2006 as a Private Foundation, the Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain, is a comprehensive cancer center of excellence where its researchers and physician-scientists adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance precision oncology against cancer.
Marking a new VHIO era towards precision oncology, we have occupied our new premises – the CELLEX building, equipped with cutting-edge facilities and technologies – financed through the support of the Cellex Private Foundation. These new facilities not only bring all of our multidisciplinary teams together under the same roof, but also afford VHIO with the critical space required to expand its programs and activities.
One such area, led by VHIO´s Growth Factors Group, centers on breast cancer research twinned with cancer immunology:
VHIO´s Growth Factors Group led by Joaquín Arribas is currently extending its basic, purely translational breast cancer research into advancing insights in oncoimmunlogy. We are inviting immediate applications from outstanding postdoctoral candidates with a strong background in immunology and cancer cell biology to spur research into immune-based personalized therapeutics.
Applicants must demonstrate excellence in multidisciplinary, collaborative and ground-breaking research as evidenced by a strong publication record, as well as the same motivational spirit, drive and energy shared by VHIO´s other rising young talents. Only candidates that have obtained their PhD after 2011 will be considered.
Application: Candidates should submit their curriculum vitae (including bibliography), a letter of motivation, and contact information of two references by email to: email@example.com and firstname.lastname@example.org.
Review of applications will commence immediately. The successful candidate will be expected to join VHIO between January – February 2016.
VHIO provides: A dynamic, multidisciplinary research environment, optimal laboratory space and access to our cutting-edge core technologies (Cancer Genomics, Translational Genomics, Proteomics, Molecular Oncology, etc.). Located in the stunning city that is Barcelona, our new research facilities also comprise an exceptional state-of-the-art animal facility.
PLEASE ALSO NOTE: early stage investigators documenting similarly notable accomplishments will also be considered for an additional postdoctoral position currently available in VHIO´s Growth Factors Group to work, with immediate effect, on preclinical models for pancreatic cancer research.
The Vall d´Hebron Institute of Oncology (VHIO): Translation toward Precision Oncology